Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues

– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC –– Objective Response Rate (ORR) Improved in Both Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy –– Re...

Related Keywords

United States , Foster City , California , American , Jacquie Ross , Melissal Johnson , Dimitry Sa Nuyten , Zimberelimab Monotherapy , Meaghan Smith , Gilead Sciences Inc , Gilead Public Affairs , Gilead Sciences , Lung Cancer Research , Astrazeneca , Sarah Cannon Research Institute , Nasdaq , Arcus Biosciences Inc , Exchange Commission , Clinically Meaningful Reduction , Death Was Observed , Domvanalimab Containing Study Arms Compared , Objective Response Rate , Both Domvanalimab Containing Study Arms Compared , Results Will Be Presented Today During , American Society , Clinical Oncology , Annual Meeting , Arcus Biosciences , Rapid Abstract Updates , Lead Investigator , Free Survival , Response Rate , Chief Medical Officer , Bill Grossman , Senior Vice President , Therapeutic Area Head , Response Evaluation Criteria , Solid Tumors , Arcus Bioscience , Private Securities Litigation Reform Act , Quarterly Report ,